eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Surgery and invasive procedures

Prior to elective surgery or invasive procedures with a moderate or high risk of bleeding1

ELIQUIS should be discontinued at least
48 hours prior to elective surgery or invasive procedures with a moderate or high risk of bleeding.

This includes interventions for which the probability of clinically significant bleeding cannot be excluded, or for which the risk of bleeding would be unacceptable.

Prior to elective surgery or invasive procedures with a low risk of bleeding1

ELIQUIS should be discontinued at least
24 hours prior to elective surgery or invasive procedures with a low risk of bleeding.

This includes interventions for which any bleeding that occurs is expected to be minimal, non-critical in its location or easily controlled.

If surgery or invasive procedure cannot be delayed1

Appropriate caution should be exercised, taking into consideration an increased risk of bleeding. This risk of bleeding should be weighed against the urgency of intervention.

Restarting ELIQUIS after surgery or invasive procedure1

ELIQUIS should be restarted after the invasive procedure or surgical intervention as soon as possible, provided the clinical situation allows and adequate haemostasis has been established.

CARDIOVERSION

ELIQUIS can be initiated or continued in patients with NVAF requiring cardioversion.1* Patients already on ELIQUIS should continue taking ELIQUIS as prescribed.1

For patients not previously treated with anticoagulants:

Confirmation should be sought prior to cardioversion that the patient has taken ELIQUIS as prescribed.1

    Dose-reduction criteria:
  • The recommended dose of ELIQUIS 5 mg twice daily should be used, unless the patient has two or more of the ABC dose-reduction criteria (age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dl [133 µmol/l] or severe renal impairment (CrCl 15–29ml/min)1
  • Patients that meet dose-reduction criteria should have a single loading dose of ELIQUIS 5 mg – this should be followed by ELIQUIS 2.5 mg twice daily at the next scheduled dose1
Diagnosemethoden

ELIQUIS is approved for a broad range of indications1

Stay on top of ELIQUIS product updates

Download guides designed for your patients


Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

CrCl = Creatinine Clearance   
NVAF = Atrial Fibrillation   
VKA = Vitamin K Antagonist

* Decisions on initiation and duration of treatment should take established guideline recommendations for anticoagulant treatment in patients undergoing cardioversion into account.1

The recommended dose of 5 mg twice daily should be used, unless the patient has two or more of the ABC dose-reduction criteria (age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dl [133 µmol/l]) or severe renal impairment (CrCl 15–29 ml/min).1

Reference

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.